It is China's first and only domestic "three-in-one" single-tablet combination Class 1 new drug for HIV treatment. As a new-generation non-nucleoside combination preparation, it has been included in the national medical insurance catalog through price negotiations and recommended by the Chinese Guidelines for the Diagnosis and Treatment of AIDS (2024 Edition).
The incidence of CNS side effects, rash and gastrointestinal adverse reactions can be significantly reduced, with significantly improved patients' tolerance.
It has little effect on lipid metabolism while reducing the risk of cardiovascular and cerebrovascular diseases, fatty liver and other diseases.
It has low hepatotoxicity and can significantly reduce liver function impairment.
It is metabolized by CYP2C19 pathway and effectively reduces the risk of DDIs.
Potent viral suppression with sustained anti-HIV efficacy.
Excellent efficacy in patients with high or low baseline viral load.
Rapid increase of CD4+ cells with continuous improvement of immune system.
